A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, . Cancer statistics, 2008. CA Cancer J Clin; 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol 1998;16:2780–95.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–61.
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Smith SM. Management of relapsed diffuse large B-cell lymphoma. Curr Oncol Rep 2008;10:393–03.
   PubMed Web of Science ®Google Scholar
• Bendandi M. Aming at a curative strategy for follicular lymphoma. CA Cancer J Clin 2008;58:305–17.
   PubMed Web of Science ®Google Scholar
• Andersen NS, Jensen MK, de Nully Brown P, Geisler CH. A Danish population-based analysis of 105 mantle cell lym-phoma patients: Incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401–8.
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;191:1644–52.
   Google Scholar
• Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B, . Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radio-pharm 1997;12:177–86.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–33.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, . Rituximab (anti-CD20 monoclonal anti-body) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927–32.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, . Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–14.
   PubMed Web of Science ®Google Scholar
• Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286–91.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, . Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1–12.
   PubMedGoogle Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horing SJ, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315:629–34.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–2.
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, . The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) sig-nificantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064–71.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 24:121–7.
   Google Scholar
• Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, . Results of a prospective randomised open label phase III study comparing rituximab plus mitoxan-trone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004;104:abstract584.
   Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, . Frontline therapy with rituximab added to the combinat ion of cylophosphamide, doxorubicin, vinc-ristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lym-phoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725–32.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–92.
   PubMed Web of Science ®Google Scholar
• Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK . Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China-a multi-center randomized trail. Ai Zheng 2005;24:1421–6.
   PubMedGoogle Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, . CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–23.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lym-phoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Rivas-Vera S, Baez E, Sobrevilla-Calvo P, Baltazar S, Tripp F, Vela J, . Is first line single agent rituximab the best treatment for indolent non-Hodgkin's Lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP. Blood 2005;106:abstract2431.
   Google Scholar
• van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, . Rituximab maintenance improves clinical outcome of relapsed/ref ractory follicular non-Hodgkin lym-phoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 inter-group trial. Blood 2006;108:3295–301.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–16.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, . Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–1.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hum-merjohann J, Waltzer U, . Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103:4416–23.
   PubMed Web of Science ®Google Scholar